Quick Answer
Corbus Pharmaceuticals Holdings, Inc. reported Research And Development Expense of $70.10 million for the year ending 2025.
- Corbus Pharmaceuticals Holdings, Inc. showed an increase of +117.5% in Research And Development Expense from 2024 to 2025.
- This data is from Corbus Pharmaceuticals Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Corbus Pharmaceuticals Holdings, Inc.'s Research And Development Expense has grown by 33,172.4%.
- Historical annual values: Fiscal year 2025: $70.10 million | Fiscal year 2024: $32.22 million | Fiscal year 2023: $31.17 million | Fiscal year 2022: $16.14 million | Fiscal year 2021: $36.45 million | Fiscal year 2020: $98.27 million | Fiscal year 2019: $89.60 million | Fiscal year 2018: $48.61 million | Fiscal year 2017: $26.04 million | Fiscal year 2016: $15.44 million | Fiscal year 2015: $5.89 million | Fiscal year 2014: $1.26 million | Fiscal year 2013: $210.7 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: